Incretin based therapeutics: Connections to vascular biology and implications for potential cardiovascular disease prevention: Editorial to: 'Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation' by Dai et al.

摘要

The incretin Glucagon like peptide-1 (GLP-1) has a well documented role in glucose-stimulated insulin release and the preservation of plasma glucose homeostasis [1]. The importance of the incretin system in glucose homeostasis is emphasised by the recent successful therapeutic exploitation of this system utilising GLP-1 receptor (GLP-1 R) agonists and inhibitors of the dipeptidyl peptidase 4 (DPP-4) enzyme in the treatment of type 2 diabetes [2].